CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Acorda Therapeutics Inc. v. Par Pharmaceutical Inc.

1:15-cv-00824

Overview

Case Number 1:15-cv-00824
Filing Date 2015-09-15
Status Terminated
Termination Date 2016-01-21
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Inc. Operating Company

Represented By

1 Attorneys Listed

Karen L. Pascale

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Plaintiff

Acorda Therapeutics Inc. Operating Company

Represented By

3 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jeremy A. Tigan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9106

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 25 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (25): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8007826
Sustained release aminopyridine composition
Filed: 2004-12-13
Issued: 2011-08-30
Active (0.5 yrs remaining) +894d PTA
Expires: 2027-05-26
US8354437
Method of using sustained release aminopyridine compositions
Filed: 2005-04-08
Issued: 2013-01-15
Active (1.4 yrs remaining) +1119d PTA
Expires: 2028-05-01
US8440703
Methods of using sustained release aminopyridine compositions
Filed: 2011-11-18
Issued: 2013-05-14
Active (5.0 yrs remaining)
Expires: 2031-11-18
US8663685
Sustained release aminopyridine composition
Filed: 2011-07-20
Issued: 2014-03-04
Expired (Term Ended)
Expires: 2025-02-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+894 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

1

Dispositive

0

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Discovery due by 9/12/2016. Status Report due by 9/19/2016. Claim Cons...
Entry #12 • 2015-12-10 Document →

Docket Entries

(29 total)
Pleading / Complaint

COMPLAINT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1788083.) - filed by Acorda Therapeutics Inc.. (Attachments: # 1 Exhibit A-D, # 2 Civil Cover Sheet)(dmp, ) (Entered: 09/16/2015)

Entry #1 • 2015-09-15
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 09/16/2015)

Entry #2 • 2015-09-15
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/11/2015. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 3/11/2018. (dmp, ) (Entered: 09/16/2015)

Entry #3 • 2015-09-15
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,007,826 B2; 8,354,437 B2; 8,440,703 B2; 8,663,685 B2;. (dmp, ) (Entered: 09/16/2015)

Entry #4 • 2015-09-15
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Acorda Therapeutics Inc.. (dmp, ) (Entered: 09/16/2015)

Entry #5 • 2015-09-15
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc